NRX Pharmaceuticals (NRXP) Total Liabilities (2017 - 2026)
NRX Pharmaceuticals (NRXP) posted quarterly Total Liabilities of $25.7 million for Q1 2026, down 21.47% year-over-year from $32.8 million in Q1 2025, and down 10.99% quarter-over-quarter from $28.9 million in Q4 2025.
NRX Pharmaceuticals (NRXP) Total Liabilities (2017 - 2026) Analysis & Trends
NRX Pharmaceuticals (NRXP) has reported Total Liabilities for 10 consecutive years, with $25.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 21.47% year-over-year to $25.7 million; the TTM figure through Mar 2026 stood at $25.7 million (down 21.47% YoY), while the FY2025 annual figure was $28.9 million, up 7.51% from the prior year.
- Total Liabilities slipped to $25.7 million in Q1 2026 per NRXP's latest filing, from $28.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $40.8 million in Q3 2025 and bottomed at $7.1 million in Q2 2022.
- Historically, Total Liabilities has averaged $22.9 million across 5 years, with a median of $22.6 million in 2023.
- Annual changes were most pronounced in 2022 — Total Liabilities tumbled 87.86% — and 2023, when it surged 219.4%.
- NRX Pharmaceuticals' Total Liabilities stood at $18.4 million in 2022, then climbed by 3.48% to $19.0 million in 2023, then surged by 41.09% to $26.9 million in 2024, then increased by 7.51% to $28.9 million in 2025, then decreased by 10.99% to $25.7 million in 2026.
- Business Quant data shows NRXP's Total Liabilities at $25.7 million in Q1 2026, $28.9 million in Q4 2025, and $40.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.09 Bn | 131.23 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.66 Bn | 77.66 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.86 Bn | 59.67 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.07 Bn | 52.93 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.87 Bn | 36.77 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.45 Bn | 28.15 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 10.03 Bn |
| 10 | NRX Pharmaceuticals | 132.34 Mn | 105.64 Mn | 426,000.00 | 34.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 25.72 Mn |
| Dec 31, 2025 | 28.89 Mn |
| Sep 30, 2025 | 40.75 Mn |
| Jun 30, 2025 | 40.45 Mn |
| Mar 31, 2025 | 32.75 Mn |
| Dec 31, 2024 | 26.87 Mn |
| Sep 30, 2024 | 23.28 Mn |
| Jun 30, 2024 | 23.66 Mn |
| Mar 31, 2024 | 18.86 Mn |
| Dec 31, 2023 | 19.05 Mn |
| Sep 30, 2023 | 19.33 Mn |
| Jun 30, 2023 | 22.62 Mn |
| Mar 31, 2023 | 22.06 Mn |
| Dec 31, 2022 | 18.41 Mn |
| Sep 30, 2022 | 8.04 Mn |
| Jun 30, 2022 | 7.08 Mn |
| Mar 31, 2022 | 11.91 Mn |
| Dec 31, 2021 | 11.92 Mn |
| Sep 30, 2021 | 36.77 Mn |
| Jun 30, 2021 | 58.31 Mn |